• Issues generally related to biopharmaceutical drugs and drug development programs, including, but not limited to: Orphan Drug Act incentives, including H.R. 1629/S.250, the Fairness in Orphan Drug Exclusivity Act; drug pricing proposals, including H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S.2164, Lower Costs, More Cures Act of 2021; access to rare disease and gene therapy drugs; education and awareness of genetic rare bone disorders; FDA approvals of drugs designed to treat rare diseases, including gene therapies; and regulatory reforms generally, including but not limited to S. 3799, the PREVENT Pandemics Act, H.R. 6000, CURES 2.0, H.R. 6963, the Accelerated Approval Integrity Act of 2022, H.R. 6996, the Accelerating Access for Patients Act; H.R. 7667, Food and Drug Amendments of 2022, and S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act. Issues pertaining to newborn screening and gene panel screening, including provisions of H.R. 482/S.350 , the Newborn Screening Saves Lives Reauthorization Act of 2021. Policies contained in and amendments offered to S.Con.Res.5, setting forth the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030; and policies contained in and amendments offered to P.L. 117-2, the American Rescue Plan Act of 2021; P.L. 117-169, Inflation Reduction Act.
• Issues generally related to biopharmaceutical drugs and drug development programs, including but not limited to drug pricing proposals, Medicaid payments, access to treatment through telehealth, and access to rare disease and gene therapy drugs. Policies contained in drug pricing proposals, including H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S.2164, Lower Costs, More Cures Act of 2021. Policies contained in 85 FR 87000, Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements. H.R. 7489, Medicaid VBPs for Patients Act or the MVP Act.
• Issues generally related to the Orphan Drug Tax Credit, including provisions in H.R. 2623, Camerons Law and H.R. 5376, Build Back Better Act.
• H.R. 785/S.2313, a bill for the relief of Maria Isabel Bueso Barrera, Alberto Bueso Mendoza, and Karla Maria Barrera De Bueso.
• Policies contained in H.R.3684, Infrastructure Investment and Jobs Act and H.R. 5376, Build Back Better Act; P.L. 117-328, Consolidated Appropriations Act, 2023

Duration: February 1, 2018 to December 31, 2022

General Issues: Health Issues, Medicare/Medicaid, Taxation/Internal Revenue Code, Immigration, Budget/Appropriations

Spending: about $620,000 (But it's complicated. Here's why.)

It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.

Agencies lobbied since 2018: U.S. Senate, House of Representatives, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS)